• +1-646-491-9876
    • +91-20-67278686

    Search

    Constipation-Pipeline Review H2 2017

    Constipation-Pipeline Review H2 2017

    • Report Code ID: RW0001881465
    • Category Life Sciences
    • No. of Pages 119
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Constipation-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Constipation-Pipeline Review H2 2017 provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

    Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain pain and vomiting. The predisposing factors include eating disorders irritable bowel syndrome and hypothyroidism overuse of laxatives (stool softeners) which over time weaken the bowel muscles stress inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Constipation-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Phase III Phase II Phase I Preclinical and Discovery stages are 4 6 10 2 3 and 1 respectively. Similarly the Universities portfolio in Discovery stages comprises 1 molecules respectively.

    Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Constipation-Overview
    Constipation-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Constipation-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Constipation-Companies Involved in Therapeutics Development
    Albireo Pharma Inc
    Allergan Plc
    Ardelyx Inc
    Astellas Pharma Inc
    Braintree Laboratories Inc
    Dong-A ST Co. Ltd.
    EA Pharma Co Ltd
    Ironwood Pharmaceuticals Inc
    Johnson & Johnson
    Kissei Pharmaceutical Co Ltd
    NGM Biopharmaceuticals Inc
    RaQualia Pharma Inc
    Sanwa Kagaku Kenkyusho Co Ltd
    SK Biopharmaceuticals Co Ltd
    Sucampo Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd
    Synergy Pharmaceuticals Inc
    Synthetic Biologics Inc
    Torrent Pharmaceuticals Ltd
    Vanda Pharmaceuticals Inc
    Yuhan Corp
    Zensun (Shanghai) Sci & Tech Co Ltd
    Constipation-Drug Profiles
    5-BIOP-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AJG-555-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-7663-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Biologic for Irritable Bowel Syndrome with Constipation-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLI-400-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLI-801-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DA-6886-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DSP-6952-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elobixibat-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ENT-01-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    J-027-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KWA-0711-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    linaclotide-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    linaclotide DR1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lovastatin-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lubiprostone-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naronapride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NGM-282-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    plecanatide-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prucalopride succinate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prucalopride succinate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    relenopride hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RQ-00000010-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SK-1202-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tenapanor hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YH-12852-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZS-06-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Constipation-Dormant Projects
    Constipation-Product Development Milestones
    Featured News & Press Releases
    Jun 27 2017 Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation
    Jun 07 2017 Synergy Pharmaceuticals Announces Acceptance of Supplemental New Drug Application (sNDA) for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation
    May 12 2017 Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
    May 09 2017 Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect on Pain at Digestive Disease Week 2017
    May 07 2017 Synergy Pharmaceuticals to Present TRULANCE (Plecanatide) Phase 3 Data at Digestive Disease Week for the Treatment of Adults with Chronic Idiopathic Constipation with Moderate to Very Severe Bloating
    May 07 2017 Synergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician Perceptions and Experiences with Chronic Idiopathic Constipation
    May 01 2017 Allergan to Present Linzess and Linaclotide Delayed Release Data at Digestive Disease Week 2017
    May 01 2017 Synergy Pharmaceuticals to Highlight New Data for TRULANCE (Plecanatide) at Digestive Disease Week
    Apr 12 2017 Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE (Plecanatide) Patent Protection Until 2032
    Mar 27 2017 Synergy Pharmaceuticals Submits Supplemental New Drug Application for TRULANCE (Plecanatide) for the Treatment of Adults with Irritable Bowel Syndrome with Constipation
    Mar 22 2017 Astellas Pharma Announces Launch of LINZESS Tablets 0.25mg in Japan
    Mar 09 2017 Ironwood Pharmaceuticals provides update on key pipeline program Linaclotide delayed release-1 at R&D Day 2017
    Feb 07 2017 Pivotal Phase 3 Data Results for TRULANCE (plecanatide) in the Treatment of Chronic Idiopathic Constipation (CIC) Published in American Journal of Gastroenterology
    Feb 01 2017 Albireo Announces Submission of New Drug Application for Elobixibat in Japan
    Jan 30 2017 Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Constipation H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Constipation-Pipeline by Albireo Pharma Inc H2 2017
    Constipation-Pipeline by Allergan Plc H2 2017
    Constipation-Pipeline by Ardelyx Inc H2 2017
    Constipation-Pipeline by Astellas Pharma Inc H2 2017
    Constipation-Pipeline by Braintree Laboratories Inc H2 2017
    Constipation-Pipeline by Dong-A ST Co. Ltd. H2 2017
    Constipation-Pipeline by EA Pharma Co Ltd H2 2017
    Constipation-Pipeline by Ironwood Pharmaceuticals Inc H2 2017
    Constipation-Pipeline by Johnson & Johnson H2 2017
    Constipation-Pipeline by Kissei Pharmaceutical Co Ltd H2 2017
    Constipation-Pipeline by NGM Biopharmaceuticals Inc H2 2017
    Constipation-Pipeline by RaQualia Pharma Inc H2 2017
    Constipation-Pipeline by Sanwa Kagaku Kenkyusho Co Ltd H2 2017
    Constipation-Pipeline by SK Biopharmaceuticals Co Ltd H2 2017
    Constipation-Pipeline by Sucampo Pharmaceuticals Inc H2 2017
    Constipation-Pipeline by Sumitomo Dainippon Pharma Co Ltd H2 2017
    Constipation-Pipeline by Synergy Pharmaceuticals Inc H2 2017
    Constipation-Pipeline by Synthetic Biologics Inc H2 2017
    Constipation-Pipeline by Torrent Pharmaceuticals Ltd H2 2017
    Constipation-Pipeline by Vanda Pharmaceuticals Inc H2 2017
    Constipation-Pipeline by Yuhan Corp H2 2017
    Constipation-Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd H2 2017
    Constipation-Dormant Projects H2 2017

    List of Figures

    Number of Products under Development for Constipation H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Albireo Pharma Inc
    Allergan Plc
    Ardelyx Inc
    Astellas Pharma Inc
    Braintree Laboratories Inc
    Dong-A ST Co. Ltd.
    EA Pharma Co Ltd
    Ironwood Pharmaceuticals Inc
    Johnson & Johnson
    Kissei Pharmaceutical Co Ltd
    NGM Biopharmaceuticals Inc
    RaQualia Pharma Inc
    Sanwa Kagaku Kenkyusho Co Ltd
    SK Biopharmaceuticals Co Ltd
    Sucampo Pharmaceuticals Inc
    Sumitomo Dainippon Pharma Co Ltd
    Synergy Pharmaceuticals Inc
    Synthetic Biologics Inc
    Torrent Pharmaceuticals Ltd
    Vanda Pharmaceuticals Inc
    Yuhan Corp
    Zensun (Shanghai) Sci & Tech Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//constipation-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//constipation-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//constipation-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments